We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Genocea Biosciences Inc (GNCA) USD0.001

Sell:$0.95 Buy:$0.97 Change: $0.0301 (3.01%)
Market closed |  Prices as at close on 27 January 2022 | Switch to live prices |
Change: $0.0301 (3.01%)
Market closed |  Prices as at close on 27 January 2022 | Switch to live prices |
Change: $0.0301 (3.01%)
Market closed |  Prices as at close on 27 January 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Genocea Biosciences, Inc. is a biopharmaceutical company that is engaged in discovering and developing cancer immunotherapies using its Antigen Lead Acquisition System (ATLAS) technology platform. The Company’s Antigen Lead Acquisition System (ATLAS) technology platform allows to identify targets based on each person’s tumor antigen-specific T cell responses. Its programs include GEN-009 is a neoantigen vaccine candidate delivering adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. Its GEN-011 program is an adoptive T cell therapy using neoantigen-targeted peripheral T cells (NPTs). The GEN-011 NPTs is preferred for ATLAS-identified anti-tumor antigens that are used to manufacture a peripheral blood-derived, tumor-specific T cell therapy.

Contact details

100 Acorn Park Dr
United States
+1 (617) 8768191

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$55.72 million
Shares in issue:
57.45 million
United States
US dollar

Key personnel

  • William Clark
    President, Chief Executive Officer, Director
  • Diantha Duvall
    Chief Financial Officer
  • Raymond Stapleton
    Executive Vice President - Pharmaceutical Sciences and Manufacturing
  • Jessica Flechtner
    Chief Scientific Officer
  • Girish Aakalu
    Chief Business Officer
  • Thomas Davis
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.